Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
JBM (Healthcare) Limited (2161.HK)
Kwun Tong, HK
JBM (Healthcare) Limited functions as an investment holding company that operates across Asia, engaging in the entire process of bringing healthcare and wellness products to market, from their conception and production to their promotion, distribution, and ultimate sale. The firm's offerings include a diverse range of consumer health products, such as its own branded traditional Chinese medicines – spanning everything from over-the-counter medications to specific medicated and non-medicated treatments. Additionally, it supplies diagnostic equipment and various pharmaceutical goods. Beyond manufacturing, JBM (Healthcare) is also involved in the buying, selling, and reselling (wholesale and retail) of Chinese medicines. Its business activities extend to the trade of medical supplies and pharmaceuticals, as well as the sale of general health and herbal products. Established in 2020, the company's main operations are directed from its headquarters in Kwun Tong, Hong Kong. JBM (Healthcare) Limited is a subsidiary entity of JBM Group (BVI) Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.42% | -0.83% | -3.24% | -14.03% | -17.59% | -10.15% | -6.27% | +109.65% | +25.79% | +10.65% | +10.65% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.7% Q1'26: +25.9% (vs Q1'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+4.2% Q1'26: +38.9% (vs Q1'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+29.9% Q1'26: +18.2% (vs Q1'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+30.4% ★ Q1'26: +27.6% (vs Q1'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+15.1% ★ Q1'26: +27.1% (vs Q1'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.3% ★ Q1'26: -4.6% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.30× Q1'26: 0.72× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
648.42M
est: 648.42M (+0.0%)
|
782.29M
est: 795.58M (-1.7%)
|
831.23M
831.23M – 831.23M
+4.5% YoY
|
935.78M
935.78M – 935.78M
+12.6% YoY
|
1.05B
1.05B – 1.05B
+12.7% YoY
|
| EBITDA |
220.73M
est: 185.64M (+18.9%)
|
298.41M
est: 227.77M (+31.0%)
|
237.98M
237.98M – 237.98M
+4.5% YoY
|
267.91M
267.91M – 267.91M
+12.6% YoY
|
301.96M
301.96M – 301.96M
+12.7% YoY
|
| EBIT |
173.39M
est: 127.30M (+36.2%)
|
246.13M
est: 156.19M (+57.6%)
|
163.19M
163.19M – 163.19M
+4.5% YoY
|
183.71M
183.71M – 183.71M
+12.6% YoY
|
207.06M
207.06M – 207.06M
+12.7% YoY
|
| Net Income |
130.46M
|
197.26M
est: 163.84M (+20.4%)
|
214.63M
214.63M – 214.63M
+31.0% YoY
|
241.66M
241.66M – 241.66M
+12.6% YoY
|
280.16M
280.16M – 280.16M
+15.9% YoY
|
| SGA |
180.21M
est: 193.21M (-6.7%)
|
185.74M
est: 237.06M (-21.6%)
|
247.69M
247.69M – 247.69M
+4.5% YoY
|
278.84M
278.84M – 278.84M
+12.6% YoY
|
314.28M
314.28M – 314.28M
+12.7% YoY
|
| EPS |
0.15
|
0.24
est: 0.20 (+20.0%)
|
0.26
0.26 – 0.26
+31.0% YoY
|
0.30
0.30 – 0.30
+12.6% YoY
|
0.34
0.34 – 0.34
+15.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 61.0K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 47.6K | 0.28% |
| 3 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 45.9K | 0.22% |
| 4 | Avantis International Equity ETF AVDE | 0.00% | 253.68 | 0.23% |
| 5 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | — | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kwong Yip Sum | Executive Chairman of the Board & CEO | 3M | male |
| Yat Wai Wong | Chief Executive Officer | 3M | male |
| Chun Leung Yim FCCA | Executive Director | 200.0K | male |
| Heung Kwan Cheng | Executive Director | 200.0K | — |
| Hoi Ki Leung | Operation Manager | — | female |
| Chun Kau Yu FCPA | Company Secretary | — | male |
| Chui Yee Lo | Marketing Director | — | female |
| Kau Lap Lam | Vice President of Finance | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2161.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
